Benzinga | Mar 22, 2021 08:08AM EDT

CureVac Reports Expansion Of CvnCoV COVID-19 Vaccine Candidate Trial Analyses To Include Phase 2b/3 Variant Specific, Efficacy Secondary Endpoint To Phase 2a

-Reuters